83.18
+2.00%
Close of 9 Nov 2026, in INR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Bal Pharma
Its shares trade on NSE under the ticker BALPHARMA.NS. It has been listed since 1 February 1995. In the fiscal year to 31 March 2026, it reported revenue of ₹3.12bn and net income of ₹62.8m. At that date it held total assets of ₹3.76bn and shareholders' equity of ₹822.3m.
Bal Pharma Ltd. is a holding company, which engages in the research, development, and commercialization of pharmaceutical products. The company is headquartered in Bangalore, Karnataka. The firm is engaged in the manufacturing and marketing of pharmaceutical formulations and active pharmaceutical ingredients (API). The company is specialized in bulk actives, prescription drugs, generics and pharma intermediates. Its focused therapeutic areas are anti-diabetes, anti-histamine, anti-inflammatory, acne treatment, gastroenterology, cardiology, and dermatology. The company offers a range of APIs, which includes antihistamine, platelet inhibitor, anti-diabetic, anti-convulsant, urinary incontinence, neuropathic pain, anti-allergy, anti-inflammatory, diuretic, and acne treatment. Its finished formulation products cover dosage forms, such as tablets, capsules, syrups, suspensions, IV infusions, ophthalmic, creams and ointments. The firm offers a range of natural medicine, which includes ANARSHA, ASHWAMED, AYURFINE, AYURFINE FORTE, AYURSULIN, IMMUWIN, LIPIVED, MENOLEAP CAPSULES, MENOLEAP SYRUP, PROLIFE, and BALPRO SYRUP.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 1 Feb 1995
- Website
- balpharma.com ↗
Leadership
Pay as last reported
- Mr. Akash MathurChief Executive Officer
- Mr. Abdul BasithCompliance Officer, Company Secretary
- Shailesh SiroyaManaging Director, Executive Director₹4.2m
- Sarika BhandariAdditional Director
- Mr. Jatish ShethAdditional Non-Executive Director
- Ms. Nicola NeeladriIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Bal Pharma Ltd specializes in anti-diabetes and anti-inflammatory pharmaceutical formulations in India.
- The company offers a wide range of APIs including antihistamine and anti-convulsant products.
- Bal Pharma Ltd provides natural medicine products such as ANARSHA and ASHWAMED in the Indian market.
Weaknesses
- The company focuses on a limited number of therapeutic areas like cardiology and dermatology.
- Bal Pharma Ltd has no presence in the global market beyond India.
- The firm's product portfolio includes only a few dosage forms such as tablets and capsules.
Opportunities
- Expanding into new therapeutic areas like gastroenterology and cardiology in India.
- Increasing the range of natural medicine products including AYURFINE FORTE and PROLIFE.
- Growing demand for anti-diabetes and anti-inflammatory drugs in the Indian healthcare sector.
Threats
- Competition from established pharmaceutical companies in India.
- Regulatory changes affecting the pharmaceutical industry in India.
- Economic downturns impacting healthcare spending in India.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.